Published in J Clin Microbiol on January 01, 2000
Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol (2002) 1.49
Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (2002) 1.46
Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals. J Clin Microbiol (2000) 1.44
Rapid identification of Candida dubliniensis using a species-specific molecular beacon. J Clin Microbiol (2000) 1.34
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol (2002) 1.30
Differentiation of Candida dubliniensis from Candida albicans on staib agar and caffeic acid-ferric citrate agar. J Clin Microbiol (2001) 1.26
Differentiation of Candida dubliniensis from Candida albicans on Pal's agar. J Clin Microbiol (2003) 1.12
Isogenic strain construction and gene targeting in Candida dubliniensis. J Bacteriol (2001) 1.06
Multilocus sequence typing reveals that the population structure of Candida dubliniensis is significantly less divergent than that of Candida albicans. J Clin Microbiol (2007) 1.06
Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (2003) 0.98
The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance. Antimicrob Agents Chemother (2002) 0.94
Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol (2004) 0.90
Rapid identification and differentiation of Candida albicans and Candida dubliniensis by capillary-based amplification and fluorescent probe hybridization. J Clin Microbiol (2002) 0.89
Casein agar: a useful medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol (2003) 0.87
Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting. J Clin Microbiol (2005) 0.87
Candida dubliniensis at a university hospital in Saudi Arabia. J Clin Microbiol (2003) 0.86
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis. Antimicrob Agents Chemother (2009) 0.86
Purpurin triggers caspase-independent apoptosis in Candida dubliniensis biofilms. PLoS One (2013) 0.82
Susceptibility of Candida dubliniensis to salivary histatin 3. Antimicrob Agents Chemother (2003) 0.78
Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections. J Clin Microbiol (2001) 0.78
One-year prevalence of Candida dublinienis in a Dutch university hospital. J Clin Microbiol (2000) 0.78
Genetic relatedness of subgingival and buccal Candida dubliniensis isolates in immunocompetent subjects assessed by RAPD-PCR. J Oral Microbiol (2009) 0.77
Candida dubliniensis encrustation of an obstructing upper renal tract calculus. BMJ Case Rep (2013) 0.75
Phenotypic and genotypic detection of Candida albicans and Candida dubliniensis strains isolated from oral mucosa of AIDS pediatric patients. Rev Inst Med Trop Sao Paulo (2017) 0.75
First report of Candida dubliniensis in the Middle East. J Clin Microbiol (2001) 0.75
Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology (1995) 8.08
Candida dubliniensis: characteristics and identification. J Clin Microbiol (1998) 4.23
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol (1997) 3.54
Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol (1998) 3.44
Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS (1997) 3.32
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Rapid identification of Candida species with species-specific DNA probes. J Clin Microbiol (1998) 2.65
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J Clin Microbiol (1995) 2.41
Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol (1998) 2.31
Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology (1999) 2.26
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol (1995) 2.06
Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (1998) 2.03
Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol (1999) 2.02
Rapid identification of Candida dubliniensis with commercial yeast identification systems. J Clin Microbiol (1999) 1.96
Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J Gen Microbiol (1992) 1.94
A novel group I intron in Candida dubliniensis is homologous to a Candida albicans intron. Gene (1996) 1.70
Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes. J Clin Microbiol (1998) 1.57
Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis. J Clin Microbiol (1999) 1.56
Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother (1999) 1.51
Candida dubliniensis: An update. Rev Iberoam Micol (1999) 1.31
Rapid identification of yeast species using three primers in a polymerase chain reaction. Mol Mar Biol Biotechnol (1993) 1.23
Presumptive identification of an emerging yeast pathogen: Candida dubliniensis (sp. nov.) reduces 2,3,5-triphenyltetrazolium chloride. FEMS Immunol Med Microbiol (1998) 1.00
Identification of CARE-2-negative Candida albicans isolates as Candida dubliniensis. Mycoses (1999) 0.96
Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A (1998) 21.41
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology (1995) 8.08
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother (2006) 4.88
The low molecular weight RNAs of Rous sarcoma virus. I. The 4 S RNA. Virology (1970) 4.64
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol (1998) 3.44
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS (1997) 3.32
An analysis of the effects of prospective reimbursement programs on hospital expenditures. Health Care Financ Rev (1981) 3.05
Evaluation of YeastIdent and Uni-Yeast-Tek yeast identification systems. J Clin Microbiol (1987) 2.74
New medium for differentiation of Cryptococcus neoformans serotype pairs. J Clin Microbiol (1982) 2.71
Evaluation of the updated Vitek yeast identification data base. J Clin Microbiol (1990) 2.45
Microbiology and potential virulence of Sporothrix cyanescens, a fungus rarely isolated from blood and skin. J Clin Microbiol (1990) 2.31
Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology (1999) 2.26
The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer (2000) 2.12
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest U.S. epidemic of sporotrichosis. J Clin Microbiol (1991) 2.09
The low molecular weight RNAs of Rous sarcoma virus. II. The 7 S RNA. Virology (1970) 2.08
Synthesis of a deoxyribonucleic acid sequence complementary to ovalbumin messenger ribonucleic acid and quantification of ovalbumin genes. J Biol Chem (1973) 2.05
Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (1998) 2.03
Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. J Clin Microbiol (1998) 2.00
Analysis of the reduction in expression of tetracycline resistance determined by transposon Tn10 in the multicopy state. Mol Gen Genet (1981) 1.97
Distinctive carbohydrate assimilation profiles used to identify the first clinical isolates of Candida dubliniensis recovered in the United States. J Clin Microbiol (1998) 1.96
Rapid identification of Candida dubliniensis with commercial yeast identification systems. J Clin Microbiol (1999) 1.96
Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J Gen Microbiol (1992) 1.94
MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol (2005) 1.93
Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther (2009) 1.90
Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis (1997) 1.87
Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. J Med Microbiol (1996) 1.81
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol (1997) 1.77
Candida dubliniensis: phylogeny and putative virulence factors. Microbiology (1998) 1.76
Evaluation of the Baxter-MicroScan 4-hour enzyme-based yeast identification system. J Clin Microbiol (1991) 1.76
The organization of a nuclear DNA sequence from a higher plant: molecular cloning and characterization of soybean ribosomal DNA. Gene (1979) 1.67
Molecular diagnosis and epidemiology of fungal infections. Med Mycol (1998) 1.64
Modification of potassium nitrate assimilation test for identification of clinically important yeasts. J Clin Microbiol (1988) 1.63
Enterobacter cloacae in a haematology/oncology ward--first impressions. J Hosp Infect (1989) 1.61
Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob Agents Chemother (2005) 1.60
Emerging pathogens. Med Mycol (2000) 1.59
Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes. J Clin Microbiol (1998) 1.57
Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol (1992) 1.56
Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems. J Clin Microbiol (1999) 1.54
Analysis of tetracycline resistance encoded by transposon Tn10: deletion mapping of tetracycline-sensitive point mutations and identification of two structural genes. J Bacteriol (1983) 1.53
Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol (2001) 1.52
Protein and enzyme electrophoresis profiles of selected Candida species. J Clin Microbiol (1989) 1.50
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology (2000) 1.47
Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) (1999) 1.46
Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting. J Clin Microbiol (1995) 1.46
Genomic DNA fingerprinting of clinical isolates of Helicobacter pylori using short oligonucleotide probes containing repetitive sequences. J Appl Bacteriol (1996) 1.45
Scedosporium inflatum: clinical spectrum of a newly recognized pathogen. J Infect Dis (1990) 1.44
Serogroup distribution of Cryptococcus neoformans in patients with AIDS. J Infect Dis (1987) 1.44
Selective IgA deficiency in connective tissue diseases. N Engl J Med (1969) 1.43
Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Manage (1995) 1.38
Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet (2000) 1.38
Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest (1995) 1.37
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer (2009) 1.34
Purification of ovalbumin messenger ribonucleic acid by specific immunoadsorption of ovalbumin-synthesizing polysomes and millipore partition of ribonucleic acid. J Biol Chem (1973) 1.34
Staphylococcal toxins in human disease. Soc Appl Bacteriol Symp Ser (1990) 1.33
Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated PHR1 and PHR2 genes of C. albicans. J Clin Microbiol (1999) 1.31
Candida dubliniensis: An update. Rev Iberoam Micol (1999) 1.31
Epidemiological typing of MRSA isolates from blood cultures taken in Irish hospitals participating in the European Antimicrobial Resistance Surveillance System (1999-2003). Eur J Clin Microbiol Infect Dis (2006) 1.30
Evaluation of Abbott Quantum II yeast identification system. J Clin Microbiol (1985) 1.30
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab (2015) 1.30
Pelvic rib. Report of a case. Radiology (1974) 1.30
Novel organization of the site-specific integration and excision recombination functions of the Staphylococcus aureus serotype F virulence-converting phages phi 13 and phi 42. Mol Microbiol (1995) 1.29
Differentiation of Candida dubliniensis from Candida albicans on staib agar and caffeic acid-ferric citrate agar. J Clin Microbiol (2001) 1.26
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2009) 1.26
Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Control Clin Trials (2000) 1.25
Natural and anthropogenic inputs of hydrocarbons to the Strait of Georgia. Sci Total Environ (1999) 1.23
beta-Glucosidase in Candida albicans and its application in yeast identification. J Clin Microbiol (1987) 1.22
Lower filamentation rates of Candida dubliniensis contribute to its lower virulence in comparison with Candida albicans. Fungal Genet Biol (2007) 1.22
Cloning and expression of the Haemophilus influenzae transferrin receptor genes. Mol Microbiol (1996) 1.18
Diagnostic characters of an atypical Candida. J Clin Microbiol (1981) 1.18
Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Infect Immun (1997) 1.17
Enhanced peripheral vasodilation in humans after a fatty meal. J Am Coll Cardiol (2000) 1.16
Clinical, microbiological, and experimental animal studies of Candida lipolytica. J Clin Microbiol (1989) 1.16
Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology (1979) 1.15
Breast tissue density quantification via digitized mammograms. IEEE Trans Med Imaging (2001) 1.15
Enterotoxin production by Staphylococcus aureus isolates from cases of septicaemia and from healthy carriers. J Med Microbiol (1989) 1.13
Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis (1997) 1.13
Molecular typing of methicillin and gentamicin resistant Staphylococcus aureus in Dublin. Eur J Clin Microbiol (1986) 1.13
Nonadditive effects of leaf litter species diversity on breakdown dynamics in a detritus-based stream. Ecology (2007) 1.12
A multistate outbreak of sporotrichosis associated with sphagnum moss. Am J Epidemiol (1992) 1.11
Evidence for negative charge in the conduction pathway of the cardiac ryanodine receptor channel provided by the interaction of K+ channel N-type inactivation peptides. J Membr Biol (1998) 1.11
MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother (2001) 1.10
Determinants of pulmonary function in patients undergoing coronary bypass operations. Ann Thorac Surg (1990) 1.10
Molecular cloning and characterization of the genetic determinant encoding CS3 fimbriae of enterotoxigenic Escherichia coli. Microb Pathog (1987) 1.09
Quantitative evaluation of the antifungal properties of cycloheximide. Antimicrob Agents Chemother (1972) 1.09
Flight muscle function in Drosophila requires colocalization of glycolytic enzymes. Mol Biol Cell (1997) 1.09
Isolation of C. dubliniensis from insulin-using diabetes mellitus patients. J Oral Pathol Med (2000) 1.09
Validation of the confusion assessment method in the palliative care setting. Palliat Med (2008) 1.09
Susceptibility to antimicrobial agents and analysis of plasmids in gentamicin- and methicillin-resistant Staphylococcus aureus from Dublin hospitals. J Med Microbiol (1985) 1.08
Angiogenesis in psoriasis. Angiogenesis (2002) 1.08
Isolation of highly encapsulated Cryptococcus neoformans serotype B from a patient in New York City. J Clin Microbiol (1986) 1.08